Rodriguez, the CEO and President of Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), recently sold shares worth $200,075, according to a recent ... Finally, in the third quarter of 2024, Rigel achieved a net ...

Rodriguez, the CEO and President of Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), recently sold shares worth $200,075 ... Rigel achieved a net income of $12.4 million, marking a significant turnaround ...

Following this transaction, O'Connell continues to hold 667,488 shares of Acumen Pharmaceuticals ... expenses totaling $27.2 million, and a net loss of $29.8 million for the quarter.

Elon Musk, recognized as both the richest man in the world and the richest person in the world, is the CEO ... are worth $14.2 trillion in aggregate. 2. Is it possible for billionaires' net ...

S&P 500 alcanza máximo histórico al cierre, a la espera de minutas de la Fed February 18, 2025 U.S.-based hedge fund Viking Global built a $526 million-worth new ... under new CEO David Joyner.

Billionaire Masayoshi Son, founder and CEO of Japanese multinational investment company SoftBank Group, is one of the richest people in the world. Considered one of the most powerful investors in the ...

WEST CONSHOHOCKEN, PA—William John Sibold, the President and CEO of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), has sold shares of the company worth $531,020. The transaction involved the sale ...

OpenAI CEO Sam Altman is a billionaire, thanks to his investments in technology companies like Reddit, Stripe, Airbnb, and more. Here's how Altman made his money.

Masayoshi Son, founder and CEO of Japanese multinational investment company SoftBank Group,has an estimated net worth of $17 billion, according to Bloomberg. Son has a 29% stake in Softbank.

Nvidia CEO Jensen Huang saw his personal fortune tumble on Monday amid turbulence in U.S. tech stocks. His net worth hit $103.7 billion by the end of the trading day, marking a $20.8 billion ...

Michael A. Metzger, Chief Executive Officer of Syndax Pharmaceuticals Inc. (NASDAQ:SNDX), recently sold 13,288 shares of the company's common stock. The clinical-stage biopharmaceutical company ...